Clinical trial
Rocuronium vs Cis-atracurium: Do Rocuronium Still 'ROCKS' In Coronary Artery Bypass Grafting
Name
IJNREC/631/2023
Description
The current trend in most cardiac surgeries was to use rocuronium as it provides faster recovery in train-of-four ratio compared to other aminosteroid non-depolarising neuromuscular blocker. However, as most cardiac centres' standard of care does not perform any neuromuscular monitoring nor antagonism of neuromuscular blockade effect, residual neuromuscular blockade could potentially be the key to delayed extubation. As such, Cis-atracurium's organ-independent Hofmann elimination could be in favour.
Trial arms
Trial start
2023-08-01
Estimated PCD
2023-11-23
Trial end
2023-11-23
Status
Completed
Treatment
Rocuronium Bromide 10 MG/ML
Comparative
Arms:
Rocuronium
Other names:
Esmeron
Nimbex 10 MG in 5 ML Injection
Comparative
Arms:
Cis-atracurium
Other names:
Cis-atracurium
Size
289
Primary endpoint
Incidence of postoperative pulmonary complication
6 months
Eligibility criteria
Inclusion Criteria:
* All patients that undergo general anaesthesia for CABG surgery requiring neuromuscular blockade of either rocuronium or cis-atracurium
Exclusion Criteria:
1. Recent history of pulmonary infection four weeks before surgery
2. Exposed to both neuromuscular blockade within 24 hours perioperatively
3. Patients intubated or on tracheostomies pre-operatively
4. Any missing or incomplete data
Protocol
{'studyType': 'OBSERVATIONAL', 'patientRegistry': False, 'designInfo': {'observationalModel': 'COHORT', 'timePerspective': 'RETROSPECTIVE'}, 'enrollmentInfo': {'count': 289, 'type': 'ACTUAL'}}
Updated at
2023-11-28
1 organization
2 products
6 indications
Organization
Institut Jantung NegaraProduct
Rocuronium BromideIndication
Neuromuscular BlockadeIndication
AtelectasisIndication
Postoperative Pulmonary ComplicationIndication
Coronary Artery DiseaseIndication
coronary artery bypass graftingIndication
Hypothermic Cardiopulmonary BypassProduct
Nimbex